Literature DB >> 6831673

Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine.

H J Duff, D Roden, R K Primm, J A Oates, R L Woosley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6831673     DOI： 10.1161/01.cir.67.5.1124

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  15 in total

Review 1.  New concepts affecting the use of antiarrhythmic agents.

Authors:  R L Woosley
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

2.  Efficacy of disopyramide and mexiletine used alone or in combination in the treatment of ventricular premature beats.

Authors:  H Sakurada; T Motomiya; M Hiraoka
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

Review 3.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 4.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 5.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 6.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

7.  Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.

Authors:  L Johannesen; J Vicente; J W Mason; C Erato; C Sanabria; K Waite-Labott; M Hong; J Lin; P Guo; A Mutlib; J Wang; W J Crumb; K Blinova; D Chan; J Stohlman; J Florian; M Ugander; N Stockbridge; D G Strauss
Journal:  Clin Pharmacol Ther       Date:  2015-11-28       Impact factor: 6.875

8.  Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias.

Authors:  T Tanabe
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

9.  Combined effects of different class I antiarrhythmic agents on maximum rate of depolarization (Vmax) of action potentials in guinea-pig papillary muscles.

Authors:  M Hiraoka; J Nitta; A Sunami; T Sawanobori
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

Review 10.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.